Merck & Co (MRK)
80.79
-3.27 (-3.90%)
NYSE · Last Trade: Jul 29th, 12:12 PM EDT
Detailed Quote
Previous Close | 84.06 |
---|---|
Open | 79.85 |
Bid | 80.76 |
Ask | 80.81 |
Day's Range | 76.66 - 81.37 |
52 Week Range | 73.31 - 127.99 |
Volume | 16,134,472 |
Market Cap | 204.50B |
PE Ratio (TTM) | 11.76 |
EPS (TTM) | 6.9 |
Dividend & Yield | 3.240 (4.01%) |
1 Month Average Volume | 12,457,024 |
Chart
About Merck & Co (MRK)
Merck & Co is a global healthcare company that specializes in the development, manufacturing, and marketing of pharmaceutical products and vaccines. The company is dedicated to improving health outcomes through innovative research and is known for its focus on areas such as oncology, infectious diseases, and immunology. In addition to its pharmaceutical offerings, Merck actively engages in the discovery of new biologics and therapies, working to address some of the most pressing health challenges worldwide. Through its commitment to scientific excellence and patient care, Merck plays a critical role in advancing public health and enhancing quality of life globally. Read More
News & Press Releases
Merck posted lower Q2 earnings as vaccine sales dropped, but oncology and animal health segments saw strong growth; 2025 guidance slightly raised.
Via Benzinga · July 29, 2025
Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Tuesday and stay ahead of the market trends.
Via Chartmill · July 29, 2025
The $3 billion will be reinvested to support new product launches and its pipeline across multiple therapeutic areas, Merck said.
Via Stocktwits · July 29, 2025
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.
Via Chartmill · July 29, 2025
Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% year on year to $15.81 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $64.8 billion at the midpoint. Its non-GAAP profit of $2.13 per share was 5% above analysts’ consensus estimates.
Via StockStory · July 29, 2025
Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2025.
By Merck & Co., Inc. · Via Business Wire · July 29, 2025
If you're looking for high-yield stocks in the healthcare sector, it's hard to beat this trio of industry giants offering yields of up to 3.9%.
Via The Motley Fool · July 28, 2025
GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 billion.
Via Benzinga · July 28, 2025
Merck Commits To Veeva’s Vault CRM, Draws Wall Street Cheer: Retail’s Not Enthusiasticmerck-com
Via Stocktwits · July 21, 2025
Merck offers a quarterly dividend amount of 81 cents per share. To receive $500 monthly, here's what you do.
Via Benzinga · July 28, 2025
These big pharma stocks arguably aren't receiving the respect they deserve.
Via The Motley Fool · July 28, 2025
Global pharmaceutical company Merck (NYSE:MRK)
will be reporting earnings this Tuesday before market open. Here’s what investors should know.
Via StockStory · July 27, 2025
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.
Via Benzinga · July 26, 2025
Merck’s Blockbuster Drug Keytruda Gets Canadian Regulator’s Approval For Treating Cervical Cancer: Retail Investors Appear Dividedstocktwits.com
Via Stocktwits · July 21, 2025
AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles.
Via Benzinga · July 25, 2025
Merck & Co. (MRK) is a top value stock with strong fundamentals—undervalued P/E, high profitability, stable finances, and steady growth, making it a smart pick for value investors.
Via Chartmill · July 25, 2025
The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst.
Via Investor's Business Daily · July 23, 2025
The company had lined up a priority review in the hopes of winning an accelerated approval for its melanoma treatment.
Via Investor's Business Daily · July 22, 2025
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company’s common stock for the fourth quarter of 2025. Payment will be made on Oct. 7, 2025 to shareholders of record at the close of business on Sept. 15, 2025.
By Merck & Co., Inc. · Via Business Wire · July 22, 2025
MERCK & CO. INC. (NYSE:MRK) is a high-quality stock with strong profitability, efficient capital use, and a reliable dividend, making it a solid pick for long-term investors.
Via Chartmill · July 22, 2025